Screener
Tarsus Pharmaceuticals, Inc. TARS Product sales, net — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product sales, net | $173,912 | $102,660 | $319,299 | $180,995 |
| License fees and collaboration revenue | — | — | 16,667 | — |
| Total revenues | 173,912 | 102,660 | 335,966 | 180,995 |
| Operating expenses: | ||||
| Cost of sales | 12,113 | 6,237 | 21,509 | 11,448 |
| Research and development | 31,010 | 15,594 | 53,361 | 30,003 |
| Selling, general and administrative | 150,697 | 103,013 | 287,126 | 188,008 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues?
- Tarsus Pharmaceuticals, Inc. (TARS) reported product sales, net — total revenues of $173.91M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues increased by 69.4% year-over-year, from $102.66M to $173.91M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues has grown at a 453.6% compound annual growth rate (CAGR), from $14.73M to $451.36M.
- What does product sales, net — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products after accounting for variable considerations such as rebates, discounts, and returns. It serves as a primary indicator of market adoption and commercial success for the company's therapeutic portfolio. Growth in this figure reflects the effective penetration of the company's products within its target ophthalmic patient population.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s product sales, net — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude